Breaking Finance News

HC Wainwright announced Karyopharm Therapeutics Inc (NASDAQ:KPTI), bumping its price target to $15.00 earlier today

Karyopharm Therapeutics Inc (NASDAQ:KPTI) had its target price raised to $15 by HC Wainwright in a report issued Thursday August 18 2016. The increased target price implies a potential upside of 0.93% based on the bussiness’ previous closing price.

Previously on Thursday August 18 2016, H.C. Wainwright reported about Karyopharm Therapeutics Inc(NASDAQ:KPTI) raised the target price from $0.00 to $15.00. At the time, this indicated a possible upside of 1.15%.

Just yesterday Karyopharm Therapeutics Inc (NASDAQ:KPTI) traded 2.09% higher at $7.76. The company’s 50-day moving average is $7.85 and its two hundred day average is $8.17. With the last close down 13.78% from the 200-day moving average, compared to the S&P 500 Index which has decreased -0.01% over the same time. 671,230 shares of Karyopharm Therapeutics Inc exchanged hands, up from ann avg. volume of 380,034.

Recent Performance Graphic:

Karyopharm Therapeutics Inc (NASDAQ:KPTI)

Karyopharm Therapeutics Inc has a one-year low of $4.83 and a 52 week high of $19.41 and has a market capitalization of $0.0.

Also covering Karyopharm Therapeutics Inc’s stock price target, a total of 9 brokers have reported on the company. The consensus target is $16.56 with three analysts rating the company a strong buy, three analysts rating the stock a buy, one analyst rating the stock a hold, one firm rating the company to underperform, and lastly 0 brokeragesrating the stock as sell.

General Information About Karyopharm Therapeutics Inc (NASDAQ:KPTI)

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, and a compound in development for the treatment of neurological disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *